The Executive Board has appointed Peter-Bram ‘t Hoen as professor of Bioinformatics with a focus on Personalized Medicine, and head of the Centre for Molecular and Biomolecular Informatics (CMBI) by 1 March 2018. As such he will be the successor of Gert Vriend.Previously, Peter-Bram 't Hoen worked at the department of Human Genetics, LUMC, Leiden. His main research interest is the impact of genetic variants on transcription, mRNA processing, translation and clinical phenotypes. At the LUMC his research was focused on automated knowledge discovery, enhanced data interoperability and publication, and e-Science approaches to ensure reproducibility and easy sharing of analysis routines. He published over 130 papers in peer-reviewed journals in the area of genetics, bioinformatics, statistics, molecular biology and medicine.
We congratulate Peter-Bram with his new appointment and welcome him to our institute.
Related news items
Jong KNCV organizes a Pitch competition for PhD candidates13 August 2020
Are you a PhD candidate and would you like to win 500 euros with a pitch about your research? Young KNCV gives you that chance! During the KNCV Chemistry 2020 Evening on October 8th.read more
Collective invasion induced by autocrine purinergic loop through connexin-43 hemichannels13 August 2020
Peter Friedl and Paul Span show in Journal of Cell Biology that breastcancer cells release purines into the extracellular space via connexin-43 hemichannels to control collective invasion.read more
TP53 allelic state is critical for diagnostic and prognostic precision in blood cancer12 August 2020
An international study, in which Joop Jansen participated, shows that a double mutaton in TP53 gene deteriotes the prognosis of a rare form of blood cancer. If there is only one mutation or no mutation, then the prognosis is better.read more
BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea11 August 2020
The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more